The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
about
The effects of desipramine and iprindole on levels of enantiomers of fluoxetine in rat brain and urineFluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevanceThe pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to ratsSSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystoniaThe effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomesHyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reportsCharacterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studiesExtrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.Summary of information on human CYP enzymes: human P450 metabolism data.The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants.The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power.Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort studyEffect of fluoxetine on pharmacokinetics of ritonavir.Modern chromatographic and electrophoretic measurements of antidepressants and their metabolites in biofluids.Coprescription of tamoxifen and medications that inhibit CYP2D6.Clinically significant pharmacokinetic interactions between dietary caffeine and medications.Antidepressants in the elderly: challenges for study design and their interpretation.Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifenPindolol augmentation of antidepressants: a review and rationale.The SSRIs: advantages, disadvantages and differences.Bupropion and sertraline combination treatment in refractory depression.Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.Toxic effects of theophylline caused by fluvoxamineInhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidineThe disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes.The clinical pharmacokinetics of darifenacin.Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifeneBJCP 40th anniversary: moving forward, looking back.Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Pathophysiology and management of the serotonin syndrome.In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine.Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyClinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Genetic variation, β-blockers, and perioperative myocardial infarction.
P2860
Q28254784-51F7EC6A-A259-4120-B80A-03DD37E57CD0Q28343761-4351226A-B868-425C-BB3A-37FC7D32C3BDQ28344876-3451BF53-42C0-4A2A-92CD-EDC33A014D91Q28373136-36EE6D41-19E0-4AF4-ABC9-238D26049901Q28378938-9AA935EE-588F-460A-90B0-5CD42E1E0AFDQ28379131-FBAB047D-5FF2-4711-96B2-2B16B9C8EAA3Q29394097-3C126292-6F3A-4B58-AE14-EDE3E642AE92Q30577448-F254FA3A-2560-4144-A4A1-5845661BC40DQ32064658-76010530-6498-461D-BF3B-20D5430CE631Q32103802-9B68A1F6-1C49-44C6-9F72-DDDE1E531BCFQ33181987-BD27678B-EE5F-4F71-AF3B-492E4466B48EQ33185514-ACA268E2-42D3-4E92-9D76-CCAB3A78D5CAQ33254664-C673CD79-7BC4-4597-8649-429D53855735Q33418816-E5C399D6-79C8-4887-820E-4B7F1AD40A35Q33634928-FB33D10A-362C-4A30-83D8-D2C1FED010ECQ33702785-0B190B57-9884-411F-B3E1-892F8809AA27Q33759563-1E41B95F-434E-46CA-84D5-B8E32775D7E6Q33898184-076EF652-C4A9-4A3F-99BF-2DD15014EE38Q33916981-8345EAE1-C266-488A-8505-2E3C4555509CQ33940219-4C6280D9-EB55-4CB7-9BF1-63633A368E41Q33940729-16C6EDD8-8C2D-48AC-917B-67167525A61AQ34143604-A0252DCE-7E22-4621-A00F-3891C952F76AQ34251176-7B6C378E-9E8A-46DA-AD0E-78338F72BF98Q34251217-80D35CAA-00F1-4C72-BBCF-63703F85FE5CQ34269371-CE80F31E-6973-486F-85E8-A43EF696E783Q34277702-E93F71F9-7F9E-4ABA-BA71-07AFF7662A04Q34346469-BD16B686-4E13-4F33-962C-0D3DC73CBFD8Q34409085-0841B56E-5415-4EE6-888E-D2AF87B7F529Q34434069-5DB5D650-414A-45D9-A12C-C4D6B0CD1E3AQ34566180-D54738E5-A765-4549-8EF1-14D7864546B6Q34568883-2C9AAACC-1FDB-4419-B3AA-81317820821AQ34635476-2978DC59-18FA-4B9A-A7F6-69D7A7BB8A08Q34650915-2A12DEC4-2765-4FC3-90F2-E5CC91BC3B52Q34653100-3BD2207A-F203-4682-A97B-3C92E2A636A7Q34662861-1EB30840-523C-4603-9215-4182E58CBCB6Q34746998-FE8A7D45-BB77-4703-AB29-DAF2C7C6BC50Q34999764-FFE424D2-8B20-4DC8-AAF4-9E6381A443AAQ35056229-11B2709E-95DA-405C-BCAF-277F2DB860E1Q35058455-9246A663-359C-4B92-8936-34D74DFB0500Q35580952-AC0789F1-7219-42A4-8014-BBD51CFFA6BF
P2860
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The effect of selective seroto ...... vity in human liver microsomes
@en
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6
@nl
type
label
The effect of selective seroto ...... vity in human liver microsomes
@en
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6
@nl
prefLabel
The effect of selective seroto ...... vity in human liver microsomes
@en
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6
@nl
P2093
P2860
P1476
The effect of selective seroto ...... vity in human liver microsomes
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1992.TB04134.X
P407
P577
1992-09-01T00:00:00Z